Treats breast cancer after failure of combination chemotherapy for metastatic disease or…. Sold as Taxol, Abraxane, Paclitaxel. Every FDA application for this active ingredient: 4 branded and 20 generic.
As of Nov 14, 2026, FDA lists 24 applications for Paclitaxel (sold as Taxol, Abraxane, Paclitaxel), first approved Dec 29, 1992, with 12 new uses approved and 0 published complete response letters.
| Paclitaxel | Part B | $1.5M | +5% | 14,134 |
| Paclitaxel | Part D | $216K | +6% | 769 |
| Clinical Study of Ivonescimab Combined With Concurrent Chemoradiotherapy in the Treatment of Advanced Non-small Cell Lung CancerConcurrent Chemoradiotherapy, Immunotherapy · Guizhou Medical University | Phase 2 | Not yet recruiting | Nov 13, 2026 |
| A Phase II Study of Nab-Paclitaxel Combined With Retlirafusp Alfa and Apatinib in Patients With Advanced Mucosal MelanomaMelanoma, Immune Checkpoint Inhibitor · Sun Yat-sen University | Phase 2 | Recruiting | Nov 13, 2026 |
| PDS Versus NACT-IDS in AI-Selected Advanced Epithelial Ovarian CancerEpithelial Ovarian Cancer, Fallopian Tube Cancers · Shanghai Gynecologic Oncology Group | Phase 2 / Phase 3 | Not yet recruiting | Nov 12, 2026 |
| Neoadjuvant Finotonlimab Plus TP Regimen in Locally Advanced INI-1-Deficient Sinonasal CarcinomaSMARCB1-Deficient Sinonasal Carcinoma · Eye & ENT Hospital of Fudan University | Phase 2 | Recruiting | Nov 10, 2026 |
| A Multicenter, Prospective Single-arm Study of Multimodal Thermal Therapy Combined With Toripalimab and AG Chemotherapy in the Treatment of Advanced Pancreatic CancerPancreatic Neoplasms, Neoplasm Metastasis · Ruijin Hospital | Not applicable | Not yet recruiting | Nov 10, 2026 |
| LDE-Paclitaxel for Cardiac Allograft Vasculopathy: A Pilot StudyHeart Transplant Recipient, Cardiac Allograft Vasculopathy · University of Sao Paulo General Hospital | Phase 2 | Active, not recruiting | Nov 10, 2026 |
| RELEASE Ph2 RT-310 BPH StudyBenign Prostatic Hyperplasia (BPH) · Resurge Therapeutics Inc. | Phase 2 | Not yet recruiting | Nov 10, 2026 |
| Induction Chemoimmunotherapy to Prevent Laryngectomy in Advanced Laryngeal Cancer and Hypopharyngeal CancerAdvanced Laryngeal Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma · Mayo Clinic | Phase 2 | Not yet recruiting | Nov 9, 2026 |
| Dec 29, 1992 | TaxolNDA 20262 · New molecular entity | Hq Spclt Pharma | 43 | Discontinued |
| Jan 25, 2002 | PaclitaxelANDA 75184 | Teva Pharms | 6 | Marketed |
| Jan 25, 2002 | PaclitaxelANDA 75278 | Pharmobedient | 3 | Discontinued |
| Jan 25, 2002 | PaclitaxelANDA 75297 | Teva Pharms USA | 4 | Discontinued |
| Jan 28, 2002 | PaclitaxelANDA 75190 | Hikma | 3 | Marketed |
| May 8, 2002 | PaclitaxelANDA 76131 | Hospira | 4 | Marketed |
| Aug 1, 2002 | PaclitaxelANDA 76233 | Hospira | 1 | Discontinued |
| Nov 12, 2004 | PaclitaxelANDA 75436 | Accord Hlthcare | 0 | Discontinued |
| Jan 7, 2005 | AbraxaneNDA 21660 · New formulation or manufacturer | Bristol-Myers | 21 | Marketed |
| Nov 27, 2006 | PaclitaxelANDA 77574 | Fresenius Kabi USA | 9 | Marketed |
| Dec 26, 2007 | PaclitaxelANDA 78167 | Sandoz | 4 | Discontinued |
| Mar 12, 2008 | PaclitaxelANDA 77413 | Pliva Lachema | 0 | Discontinued |
| Dec 9, 2009 | PaclitaxelANDA 90130 | Actavis Totowa | 3 | Marketed |
| Sep 29, 2011 | PaclitaxelANDA 91540 | Natco Pharma USA | 0 | Discontinued |
| Aug 23, 2016 | PaclitaxelANDA 207326 | Gland | 0 | Marketed |
| Aug 17, 2018 | PaclitaxelANDA 205720 | Accord Hlthcare | 0 | Marketed |
| Aug 24, 2020 | PaclitaxelANDA 213434 | Msn | 0 | Marketed |
| Jul 27, 2022 | PaclitaxelNDA 211875 · New formulation or manufacturer | Am Regent | 0 | Marketed |
| Oct 20, 2022 | PaclitaxelANDA 216874 | Alembic | 0 | Marketed |
| May 11, 2023 | PaclitaxelNDA 216338 · New formulation or manufacturer | Teva Pharms Inc | 1 | Marketed |
| Oct 8, 2024 | PaclitaxelANDA 212700 | Hengrui Pharma | 1 | Marketed |
| Apr 10, 2025 | PaclitaxelANDA 209657 | Cipla | 0 | Marketed |
| May 15, 2025 | PaclitaxelANDA 216355 | Shuangcheng | 0 | Marketed |
| Aug 19, 2025 | PaclitaxelANDA 217877 | Mylan | 0 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
Hikma
Accord Hlthcare
Fresenius Kabi USA
Sandoz
Alembic
Cipla
Mylan